Senior insider sale
CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. — senior position signals high conviction
$2.27M
6.64K shares
What this filing means
FITZGERALD KEVIN JOSEPH plans to sell 6.64K shares of ALNYLAM PHARMACEUTICALS, INC. valued at approximately $2.27M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 3/5/2026ACC: 0001969223-26-000296
Officer· CSO & EVP, Head of Research
Since Mar 2026
6.64K
Shares to sell
$2.27M
Approx. market value
658.00
Acquired (3 months)
1
Planned
3 completed
Securities Acquired — Last 3 Months1
RSU
NA
3/3/2026
658.00Total acquired658.00
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
3/3/2026 | RSU NA | 658.00 | — |
| Total | 658.00 | ||
Planned & Completed Dispositions4
Completed
—Completed
Units to sell
1.65K
Market value
$528.2K
3/3/2026
—Completed
Units to sell
2.04K
Market value
$677.5K
2/17/2026
—Completed
Units to sell
2.29K
Market value
$848.1K
1/13/2026
Planned — Approximate Date
NasdaqPlanned
Units to sell
658.00
Market value
$213.0K
3/5/2026
Total
Units
6.64K
Value
$2.27M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
3/3/2026 | 1.65K | $528.2K | — | Completed |
2/17/2026 | 2.04K | $677.5K | — | Completed |
1/13/2026 | 2.29K | $848.1K | — | Completed |
| Planned — Approximate Date | ||||
3/5/2026 | 658.00 | $213.0K | Nasdaq | Planned |
| Total | 6.64K | $2.27M | ||